Diego A. Díaz García, Medical Oncologist / CEO / Founder at CánCare – Advanced Specialty in Oncology, shared a post on LinkedIn:
“Immune checkpoint inhibitors may extend survival in EGFR-TKI–resistant NSCLC.
A meta-analysis of eight randomized trials including 2,269 patients with advanced EGFR-mutant NSCLC resistant to EGFR-TKIs found that adding immune checkpoint inhibitors (ICIs) to chemotherapy with or without antiangiogenic agents significantly improved outcomes compared with chemotherapy/antiangiogenic therapy alone.
Median progression-free survival improved by 33% (HR 0.67, p<0.001), overall survival by 11% (HR 0.89, p=0.031), and objective response rate by 20% (RR 0.80, p<0.001). Benefits were most pronounced in patients with PD-L1 expression ≥50%, Leu858Arg mutations, absence of Thr790Met, and those treated with pemetrexed-platinum.
No significant increase in grade ≥3 adverse events was observed, although discontinuations and specific toxicities such as rash, hypothyroidism, and hypertension were more frequent with ICI combinations.”
Title: Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Chemotherapy-Naïve Advanced Non–Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized Trials
Authors: Letian Huang, Shuling Zhang, Li Sun, Jietao Ma, Chengbo Han
Read the Full Article.
More posts featuring Diego A. Díaz García.